Literatur
-
1
Immunisation against hepatitis B.
Lancet.
1988;
1
875-876
-
2
European Consensus Group on Hepatitis B Immunity .
Are booster immunisations needed for lifelong hepatitis B immunity?.
Lancet.
2000;
355
561-565
-
3
Ahmed A, Keeffe E B.
Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection.
Am J Gastroenterol.
1999;
94
249-251
-
4
Anandh U, Bastani B, Ballal S.
Granulocyte-macrophage colony-stimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients.
Am J Nephrol.
2000;
20
53-56
-
5
Anselmo D M, Ghobrial R M, Jung L C. et al .
New era of liver transplantation for hepatitis B: a 17-year single-center experience.
Ann Surg.
2002;
235
611-619
-
6
Arribas J R, Gonzalez-Garcia J J, Lorenzo A. et al .
Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain.
AIDS.
2005;
19
1361-1365
-
7
Arslan M, Wiesner R H, Sievers C. et al .
Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease.
Liver Transpl.
2001;
7
314-320
-
8
Ascherio A, Zhang S M, Hernan M A. et al .
Hepatitis B vaccination and the risk of multiple sclerosis.
N Engl J Med.
2001;
344
327-332
-
9
Averhoff F, Mahoney F, Coleman P. et al .
Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection.
Am J Prev Med.
1998;
15
1-8
-
10
Awerkiew S, Daumer M, Reiser M. et al .
Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient.
J Clin Virol.
2007;
38
83-86
-
11
Ayoola E A, Johnson A O.
Hepatitis B vaccine in pregnancy: immunogenicity, safety and transfer of antibodies to infants.
Int J Gynaecol Obstet.
1987;
25
297-301
-
12
Aziz A, Aziz S, Li D S. et al .
Efficacy of repeated high-dose hepatitis B vaccine (80 microg) in patients with chronic liver disease.
J Viral Hepat.
2006;
13
217-221
-
13
Bae S H, Yoon S K, Choi J Y. et al .
Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis.
J Gastroenterol Hepatol.
2005;
20
1527-1532
-
14
Banatvala J, Van Damme P, Oehen S.
Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory.
Vaccine.
2000;
19
877-885
-
15
Bauer T, Jilg W.
Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination.
Vaccine.
2006;
24
572-577
-
16
Benhamou Y.
Treatment algorithm for chronic hepatitis B in HIV-infected patients.
J Hepatol.
2006;
44
S90-S94
-
17
Benhamou Y, Bochet M, Thibault V. et al .
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.
Hepatology.
1999;
30
1302-1306
-
18
Benhamou Y, Thibault V, Vig P. et al .
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.
J Hepatol.
2006;
44
62-67
-
19
Benner K G, Lee R G, Keeffe E B. et al .
Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation.
Gastroenterology.
1992;
103
1307-1312
-
20
Benvegnu L, Fattovich G, Noventa F. et al .
Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study.
Cancer.
1994;
74
2442-2448
-
21
Berger A, Doerr H W, Rabenau H F. et al .
High frequency of HCV infection in individuals with isolated antibody to hepatitis B core antigen.
Intervirology.
2000;
43
71-76
-
22
Bienzle U, Gunther M, Neuhaus R. et al .
Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease.
Hepatology.
2003;
38
811-819
-
23
Bodsworth N, Donovan B, Nightingale B N.
The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men.
J Infect Dis.
1989;
160
577-582
-
24
Bodsworth N J, Cooper D A, Donovan B.
The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state.
J Infect Dis.
1991;
163
1138-1140
-
25
Bortolotti F.
Treatment of chronic hepatitis B in children.
J Hepatol.
2003;
39 (Suppl 1)
S200-S205
-
26
Bortolotti F, Guido M, Bartolacci S. et al .
Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study.
Hepatology.
2006;
43
556-562
-
27
Bortolotti F, Jara P, Barbera C. et al .
Long term effect of alpha interferon in children with chronic hepatitis B.
Gut.
2000;
46
715-718
-
28
Brook G.
Prevention of viral hepatitis in HIV co-infection.
J Hepatol.
2006;
44
S104-S107
-
29
Brook M G, Chan G, Yap I. et al .
Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection.
BMJ.
1989;
299
652-656
-
30
Brook M G, McDonald J A, Karayiannis P. et al .
Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response.
Gut.
1989;
30
1116-1122
-
31
Bruguera M, Rodicio J L, Alcazar J M. et al .
Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients.
Vaccine.
1990;
8 (Suppl)
S47-S49
-
32
Brunetto M R, Oliveri F, Coco B. et al .
Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study.
J Hepatol.
2002;
36
263-270
-
33
Buti M, Jardi R, Allende H. et al .
Chronic delta hepatitis: is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections?.
J Med Virol.
1996;
49
66-69
-
34
Bzowej N, Chan H L, Lai C L. et al .
A randomized trial of telbivudine vs adefovir for HBeAg-positive chronic hepatitis B.
Hepatology.
2006;
44
563A
-
35
Cacciola I, Pollicino T, Squadrito G. et al .
Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.
N Engl J Med.
1999;
341
22-26
-
36
Cardell K, Fryden A, Normann B.
Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practise.
Scand J Infect Dis.
1999;
31
197-200
-
37
Caredda F, Rossi E, d'Arminio M A. et al .
Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable disease with different outcome.
J Infect Dis.
1985;
151
925-928
-
38
Carlsson T, Struve J, Sonnerborg A. et al .
The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination.
Scand J Infect Dis.
1999;
31
93-95
-
39
Castells L, Vargas V, Rodriguez F. et al .
Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
Liver Transpl.
2002;
8
892-900
-
40
Castelnau C, Le Gal F, Ripault M P. et al .
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
Hepatology.
2006;
44
728-735
-
41
CDC .
Recombinant Hepatitis B Vaccine and the Risk of Multiple Sclerosis. Electronic Citation.
2004;
, www.cdc.gov/ncidod/diseases/hepatitis/b/hbv_ms.pdf
-
42
Chalasani N, Smallwood G, Halcomb J. et al .
Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation?.
Liver Transpl Surg.
1998;
4
128-132
-
43
Chan H L, Leung N W, Hui A Y. et al .
A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.
Ann Intern Med.
2005;
142
240-250
-
44
Chan H L, Tang J L, Tam W. et al .
The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis.
Aliment Pharmacol Ther.
2001;
15
1899-1905
-
45
Chang T T, Gish R G, Man de R. et al .
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
N Engl J Med.
2006;
354
1001-1010
-
46
Chang T T, Shiffman M, Tong M. et al .
Durability of HBeAg seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB).
Journal of Hepatology.
2004;
40
126
-
47
Charest A F, McDougall J, Goldstein M B.
A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients.
Am J Kidney Dis.
2000;
36
976-982
-
48
Chen C J, Yang H I, Su J. et al .
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
JAMA.
2006;
295
65-73
-
49
Chen G, Lin W, Shen F. et al .
Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study.
Am J Gastroenterol.
2006;
101
1797-1803
-
50
Chen J C, Chang M L, Lin J N. et al .
Comparison of childhood hepatic malignancies in a hepatitis B hyper-endemic area.
World J Gastroenterol.
2005;
11
5289-5294
-
51
Chen P M, Chiou T J, Fan F S. et al .
Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation.
Transplantation.
1999;
67
1425-1433
-
52
Chen P M, Fan S, Liu C J. et al .
Changing of hepatitis B virus markers in patients with bone marrow transplantation.
Transplantation.
1990;
49
708-713
-
53
Chen Y C, Sheen I S, Chu C M. et al .
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection.
Gastroenterology.
2002;
123
1084-1089
-
54
Cheng A L.
Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma.
Blood.
1996;
87
1202
-
55
Cheng A L, Hsiung C A, Su I J. et al .
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.
Hepatology.
2003;
37
1320-1328
-
56
Chien R N, Yeh C T, Tsai S L. et al .
Determinants for sustained HBeAg response to lamivudine therapy.
Hepatology.
2003;
38
1267-1273
-
57
Christensen C, Bruden D, Livingston S. et al .
Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients.
J Viral Hepat.
2006;
13
652-658
-
58
Chu C M, Liaw Y F.
Hepatitis B virus-related cirrhosis: natural history and treatment.
Semin Liver Dis.
2006;
26
142-152
-
59
Chu C M, Yeh C T, Liaw Y F.
Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus.
Gut.
1999;
45
613-617
-
60
Chuang W L, Dai C Y, Chang W Y. et al .
Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Antivir Ther.
2005;
10
125-133
-
61
Clark F L, Drummond M W, Chambers S. et al .
Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma.
Ann Oncol.
1998;
9
385-387
-
62
Clemens R, Sanger R, Kruppenbacher J. et al .
Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule - results of a post-marketing surveillance.
Vaccine.
1997;
15
349-352
-
63
Coates T, Wilson R, Patrick G. et al .
Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines.
Clin Ther.
2001;
23
392-403
-
64
Cockcroft D W, Gault M H.
Prediction of creatinine clearance from serum creatinine.
Nephron.
1976;
16
31-41
-
65
Cohard M, Poynard T, Mathurin P. et al .
Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis.
Hepatology.
1994;
20
1390-1398
-
66
Colloredo G, Bellati G, Leandro G. et al .
Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new „gray-zone” for the evaluation of „borderline” values.
J Hepatol.
1996;
25
644-648
-
67
Colloredo M G, Bellati G, Leandro G. et al .
Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations.
Arch Virol.
1993;
(Suppl 8)
203-211
-
68
Colonno R J, Rose R, Baldick C J. et al .
Entecavir resistance is rare in nucleoside naive patients with hepatitis B.
Hepatology.
2006;
44
1656-1665
-
69
Colonno R J, Rose R E, Pokornowski K. et al .
Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naïve patients while resistance emergence increases over time in lamivudine refractory patients.
Hepatology.
2006;
44
229A-230A
-
70
Confavreux C, Suissa S, Saddier P. et al .
Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group.
N Engl J Med.
2001;
344
319-326
-
71
Cooksley W G.
Treatment with interferons (including pegylated interferons) in patients with hepatitis B.
Semin Liver Dis.
2004;
24 (Suppl 1)
45-53
-
72
Cooksley W G, Piratvisuth T, Lee S D. et al .
Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.
J Viral Hepat.
2003;
10
298-305
-
73
Cortelezzi A, Vigano M, Zilioli V R. et al .
Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H.
J Clin Virol.
2006;
35
467-469
-
74
Cotonat T, Quiroga J A, Lopez-Alcorocho J M. et al .
Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.
Hepatology.
2000;
31
502-506
-
75
Craxi A, Di Bona D, Camma C.
Interferon-alpha for HBeAg-positive chronic hepatitis B.
J Hepatol.
2003;
39 (Suppl 1)
S99-S105
-
76
Crespo J, Fabrega E, Casafont F. et al .
Severe clinical course of de novo hepatitis B infection after liver transplantation.
Liver Transpl Surg.
1999;
5
175-183
-
77
Crespo J, Lozano J L, Echevarria S. et al .
Influence of hepatitis C virus infection and human immunodeficiency on the natural history of chronic delta hepatitis.
Rev Esp Enferm Dig.
1994;
85
185-191
-
78
D'Antiga L, Aw M, Atkins M. et al .
Combined lamivudine/interferon-alpha treatment in „immunotolerant” children perinatally infected with hepatitis B: a pilot study.
J Pediatr.
2006;
148
228-233
-
79
Dahmen A, Herzog-Hauff S, Bocher W O. et al .
Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B.
J Med Virol.
2002;
66
452-460
-
80
Dai M S, Chao T Y.
Lamivudine therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy: prophylactic or preemptive?.
Breast Cancer Res Treat.
2005;
92
95-96
-
81
Dai M S, Wu P F, Lu J J. et al .
Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study.
Support Care Cancer.
2004;
12
191-196
-
82
Davies S E, Portmann B C, O'Grady J G. et al .
Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis.
Hepatology.
1991;
13
150-157
-
83
De Feo T M, Poli F, Mozzi F. et al .
Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study.
Transplant Proc.
2005;
37
1238-1239
-
84
De Maria N, Colantoni A, Friedlander L. et al .
The impact of previous HBV infection on the course of chronic hepatitis C.
Am J Gastroenterol.
2000;
95
3529-3536
-
85
del Canho R, Grosheide P M, Mazel J A. et al .
Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982 - 1992: protective efficacy and long-term immunogenicity.
Vaccine.
1997;
15
1624-1630
-
86
del C anho R, Grosheide P M, Voogd M. et al .
Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes.
J Med Virol.
1993;
41
30-34
-
87
Delaugerre C, Marcelin A G, Thibault V. et al .
Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
Antimicrob Agents Chemother.
2002;
46
1586-1588
-
88
Dervite I, Hober D, Morel P.
Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab.
N Engl J Med.
2001;
344
68-69
-
89
Deutsch J, Wirth S.
Konsensus über die Behandlung der chronischen Hepatitis B im Kindesalter.
Monatsschr Kinderheilkd.
2002;
150
625-629
-
90
Dhedin N, Douvin C, Kuentz M. et al .
Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc.
Transplantation.
1998;
66
616-619
-
91
Di Bisceglie A, Lai C L, Gane E. et al .
Telbivudine GLOBE trial: Maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients.
Hepatology.
2006;
44
230A-231A
-
92
Di Marco V, Giacchino R, Timitilli A. et al .
Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study.
J Viral Hepat.
1996;
3
123-128
-
93
Di Marco V, Marzano A, Lampertico P. et al .
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.
Hepatology.
2004;
40
883-891
-
94
Di Martino V, Lunel F, Cadranel J F. et al .
Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B.
J Viral Hepat.
1996;
3
253-260
-
95
Di Martino V, Thevenot T, Boyer N. et al .
Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus-infected patients.
Hepatology.
2000;
31
1030-1031
-
96
Di Martino V, Thevenot T, Colin J F. et al .
Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.
Gastroenterology.
2002;
123
1812-1822
-
97
Dickson R C, Everhart J E, Lake J R. et al .
Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.
Gastroenterology.
1997;
113
1668-1674
-
98
Dienstag J L.
The role of liver biopsy in chronic hepatitis C.
Hepatology.
2002;
36
S152-S160
-
99
Dienstag J L.
The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B.
J Hepatol.
2005;
42
158-162
-
100
Dienstag J L, Cianciara J, Karayalcin S. et al .
Durability of serologic response after lamivudine treatment of chronic hepatitis B.
Hepatology.
2003;
37
748-755
-
101
Dienstag J L, Schiff E R, Wright T L. et al .
Lamivudine as initial treatment for chronic hepatitis B in the United States.
N Engl J Med.
1999;
341
1256-1263
-
102
Dikici B, Bosnak M, Bosnak V. et al .
Combination therapy for children with chronic hepatitis B virus infection.
J Gastroenterol Hepatol.
2002;
17
1087-1091
-
103
Dikici B, Ozgenc F, Kalayci A G. et al .
Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study.
J Gastroenterol Hepatol.
2004;
19
127-133
-
104
Dore G J, Cooper D A, Barrett C. et al .
Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee.
J Infect Dis.
1999;
180
607-613
-
105
Douglas D D, Rakela J, Wright T L. et al .
The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient.
Liver Transpl Surg.
1997;
3
105-111
-
106
Duclos P.
Safety of immunisation and adverse events following vaccination against hepatitis B.
Expert Opin Drug Saf.
2003;
2
225-231
-
107
Endo T, Sakai T, Fujimoto K. et al .
A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
Bone Marrow Transplant.
2001;
27
433-436
-
108
Erhardt A, Blondin D, Hauck K. et al .
Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.
Gut.
2005;
54
1009-1013
-
109
Erhardt A, Gerlich W, Starke C. et al .
Treatment of chronic hepatitis delta with pegylated interferon-alpha2b.
Liver Int.
2006;
26
805-810
-
110
Erhardt A, Sagir A, Guillevin L. et al .
Successful treatment of hepatitis B virus associated polyarteritis nodosa with a combination of prednisolone, alpha-interferon and lamivudine.
J Hepatol.
2000;
33
677-683
-
111
Evans T G, Schiff M, Graves B. et al .
The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination.
Clin Nephrol.
2000;
54
138-142
-
112
Fabrizi F, Martin P, Dixit V. et al .
HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies.
Am J Transplant.
2005;
5
2913-2921
-
113
Fabrizio F, Bunnapradist S, Martin P.
Transplanting kidneys from donors with prior hepatitis B infection: one response to the organ shortage.
J Nephrol.
2002;
15
605-613
-
114
Farci P, Mandas A, Coiana A. et al .
Treatment of chronic hepatitis D with interferon alfa-2a.
N Engl J Med.
1994;
330
88-94
-
115
Farci P, Roskams T, Chessa L. et al .
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis.
Gastroenterology.
2004;
126
1740-1749
-
116
Farci P, Smedile A, Lavarini C. et al .
Delta hepatitis in inapparent carriers of hepatitis B surface antigen. A disease simulating acute hepatitis B progressive to chronicity.
Gastroenterology.
1983;
85
669-673
-
117
Farrell G C.
Immunosuppression and reactivation of hepatitis B in the lamivudine era: opportunities for prevention and exploitation?.
J Gastroenterol Hepatol.
1999;
14
741-744
-
118
Fattovich G, Boscaro S, Noventa F. et al .
Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B.
J Infect Dis.
1987;
155
931-935
-
119
Fattovich G, Brollo L, Boscaro S. et al .
Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B.
J Hepatol.
1989;
9
331-337
-
120
Fattovich G, Giustina G, Christensen E. et al .
Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep).
Gut.
2000;
46
420-426
-
121
Firpi R J, Nelson D R.
Viral hepatitis: manifestations and management strategy.
Hematology Am Soc Hematol Educ Program.
2006;
375-380
-
122
Flink H J, Zonneveld van M, Hansen B E. et al .
Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
Am J Gastroenterol.
2006;
101
297-303
-
123
Floreani A, Boninsegna S, Lobello S. et al .
Fatal hepatic decompensation in a bone marrow transplant recipient with HBV-related cirrhosis following lamivudine withdrawal.
Gastroenterol Clin Biol.
2006;
30
307-309
-
124
Fontana R J, Hann H W, Perrillo R P. et al .
Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy.
Gastroenterology.
2002;
123
719-727
-
125
Fontana R J, Keeffe E B, Carey W. et al .
Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.
Liver Transpl.
2002;
8
433-439
-
126
Fornairon S, Pol S, Legendre C. et al .
The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection.
Transplantation.
1996;
62
297-299
-
127
Fouillard L, Serfaty L, Gozlan J.
Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation.
Bone Marrow Transplant.
2006;
37
625-626
-
128
Fukuda R, Ishimura N, Kushiyama Y. et al .
Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver.
J Hepatol.
1997;
26
455-461
-
129
Fung S K, Chae H B, Fontana R J. et al .
Virologic response and resistance to adefovir in patients with chronic hepatitis B.
J Hepatol.
2006;
44
283-290
-
130
Fung S K, Wong F, Hussain M. et al .
Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B.
J Viral Hepat.
2004;
11
432-438
-
131
Fytili P, Ciesek S, Manns M P. et al .
Anti-HBc seroconversion after transplantation of anti-HBc positive nonliver organs to anti-HBc negative recipients.
Transplantation.
2006;
81
808-809
-
132
Gan S I, Devlin S M, Scott-Douglas N W. et al .
Lamivudine for the treatment of membranous glomerulopathy secondary to chronic Hepatitis B infection.
Can J Gastroenterol.
2005;
19
625-629
-
133
Gane E, Pilmore H.
Management of chronic viral hepatitis before and after renal transplantation.
Transplantation.
2002;
74
427-437
-
134
Ganem D, Prince A M.
Hepatitis B virus infection - natural history and clinical consequences.
N Engl J Med.
2004;
350
1118-1129
-
135
Garripoli A, Di Marco V, Cozzolongo R. et al .
Ribavirin treatment for chronic hepatitis D: a pilot study.
Liver.
1994;
14
154-157
-
136
Gaudin J L, Trepo C.
Therapy of chronic delta hepatitis with alpha- and beta-interferon.
Prog Clin Biol Res.
1993;
382
345-352
-
137
Geier M R, Geier D A.
Immunologic reactions and hepatitis B vaccine.
Ann Intern Med.
2001;
134
1155
-
138 Gerlich W H, Thomssen R. Terminology, structure and laboratory diagnosis of hepatitis viruses. Bircher J, Benhamou JP, McIntyre N, Rizetto M, Rhodes J Oxford Textbook of Clinical Hepatology Oxford; Oxford University press 1999: 828-869
-
139
Ghany M G, Ayola B, Villamil F G. et al .
Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.
Hepatology.
1998;
27
213-222
-
140
Gigliotti A R, Fioredda F, Giacchino R.
Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation.
J Pediatr Hematol Oncol.
2003;
25
184-192
-
141
Girard M.
Autoimmune hazards of hepatitis B vaccine.
Autoimmun Rev.
2005;
4
96-100
-
142
Gish R G, Chang T T, Man R A. et al .
Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022).
Hepatology.
2005;
42
267A-268A
-
143
Govindarajan de S, Chin K P, Redeker A G. et al .
Fulminant B viral hepatitis: role of delta agent.
Gastroenterology.
1984;
86
1417-1420
-
144
Gregorio G V, Jara P, Hierro L. et al .
Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial.
Hepatology.
1996;
23
700-707
-
145
Grob P, Jilg W, Bornhak H. et al .
Serological pattern „anti-HBc alone”: report on a workshop.
J Med Virol.
2000;
62
450-455
-
146
Gunsar F, Akarca U S, Ersoz G. et al .
Two-year interferon therapy with or without ribavirin in chronic delta hepatitis.
Antivir Ther.
2005;
10
721-726
-
147
Hadler S C, Alcala D M, Rivero D. et al .
Epidemiology and long-term consequences of hepatitis delta virus infection in the Yucpa Indians of Venezuela.
Am J Epidemiol.
1992;
136
1507-1516
-
148
Hadler S C, Monzon de M, Ponzetto A. et al .
Delta virus infection and severe hepatitis. An epidemic in the Yucpa Indians of Venezuela.
Ann Intern Med.
1984;
100
339-344
-
149
Hadler S C, Francis D P, Maynard J E. et al .
Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men.
N Engl J Med.
1986;
315
209-214
-
150
Hadler S C, Judson F N, O'Malley P M. et al .
Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection.
J Infect Dis.
1991;
163
454-459
-
151
Hadziyannis S J, Papatheodoridis G V, Dimou E. et al .
Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
Hepatology.
2000;
32
847-851
-
152
Hadziyannis S J, Sevastianos V, Rapti I. et al .
Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil treatment in HBeAg-negative chronic hepatitis B.
Hepatology.
2006;
44
231A
-
153
Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al .
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
N Engl J Med.
2005;
352
2673-2681
-
154
Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al .
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years.
Gastroenterology.
2006;
131
1743-1751
-
155
Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al .
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
N Engl J Med.
2003;
348
800-807
-
156
Hartman C, Berkowitz D, Eshach-Adiv O. et al .
Long-term lamivudine therapy for chronic hepatitis B infection in children unresponsive to interferon.
J Pediatr Gastroenterol Nutr.
2006;
43
494-498
-
157
Hartwig M G, Patel V, Palmer S M. et al .
Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation.
Transplantation.
2005;
80
320-325
-
158
Hasselhorn H M, Kralj N, Hofmann F. et al .
Non- and low-response after preventive hepatitis B vaccination.
Gesundheitswesen.
1997;
59
321-328
-
159
Heintges T, Petry W, Kaldewey M. et al .
Combination therapy of active HBsAg vaccination and interferon-alpha in interferon-alpha nonresponders with chronic hepatitis B.
Dig Dis Sci.
2001;
46
901-906
-
160
Henderson E A, Louie T J, Ramotar K. et al .
Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers.
Infect Control Hosp Epidemiol.
2000;
21
264-269
-
161
Hernan M A, Jick S S, Olek M J. et al .
Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study.
Neurology.
2004;
63
838-842
-
162
Hillis W D, Hillis A, Walker W G.
Hepatitis B surface antigenemia in renal transplant recipients. Increased mortality risk.
JAMA.
1979;
242
329-332
-
163
Hoff J, Bani-Sadr F, Gassin M. et al .
Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens.
Clin Infect Dis.
2001;
32
963-969
-
164
Hom X, Little N R, Gardner S D. et al .
Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection.
Pediatr Infect Dis J.
2004;
23
441-445
-
165
Hoofnagle J H, Seeff L B.
Peginterferon and ribavirin for chronic hepatitis C.
N Engl J Med.
2006;
355
2444-2451
-
166
Housset C, Pol S, Carnot F. et al .
Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus.
Hepatology.
1992;
15
578-583
-
167
Hsu Y S, Chien R N, Yeh C T. et al .
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.
Hepatology.
2002;
35
1522-1527
-
168
Hui A Y, Chan H L, Cheung A Y. et al .
Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon.
Aliment Pharmacol Ther.
2005;
22
519-528
-
169
Hui C K, Cheung W W, Au W Y. et al .
Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy.
Gut.
2005;
54
1597-1603
-
170
Hui C K, Cheung W W, Zhang H Y. et al .
Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy.
Gastroenterology.
2006;
131
59-68
-
171
Hui C K, Lau E, Wu H. et al .
Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection.
J Clin Virol.
2006;
35
185-192
-
172
Huo T I, Wu J C, Lai C R. et al .
Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection.
J Hepatol.
1996;
25
439-444
-
173
Iannitto E, Minardi V, Calvaruso G. et al .
Hepatitis B virus reactivation and alemtuzumab therapy.
Eur J Haematol.
2005;
74
254-258
-
174
Idilman R, Arat M, Soydan E. et al .
Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies.
J Viral Hepat.
2004;
11
141-147
-
175
Idilman R, Colantoni A, De Maria N. et al .
Impaired antibody response rates after high dose short interval hepatitis B virus vaccination of immunosuppressed individuals.
Hepatogastroenterology.
2003;
50
217-221
-
176
Ikeda K, Shiga Y, Takahashi A. et al .
Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.
Leuk Lymphoma.
2006;
47
155-157
-
177
Ilan Y, Ashur Y, Tur-Kaspa R. et al .
Chronic hepatitis C virus infection with exposure to hepatitis B virus.
Isr J Med Sci.
1994;
30
259-263
-
178
Iloeje U H, Yang H I, Su J. et al .
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.
Gastroenterology.
2006;
130
678-686
-
179
Imbert-Bismut F, Ratziu V, Pieroni L. et al .
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study.
Lancet.
2001;
357
1069-1075
-
180
Institute of Medicine - Report .
Hepatitis B vaccine and demyelinating neurological disorders. Electronic Citation.
2002;
, www.cdc.gov/nip/vaccine/hep/hepb/iom.htm
-
181
Iwai K, Tashima M, Itoh M. et al .
Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period.
Bone Marrow Transplant.
2000;
25
105-108
-
182
Jang J W, Choi J Y, Bae S H. et al .
Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma.
J Hepatol.
2004;
41
427-435
-
183
Jang J W, Choi J Y, Bae S H. et al .
A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization.
Hepatology.
2006;
43
233-240
-
184
Janssen H L, Zonneveld van M, Senturk H. et al .
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
Lancet.
2005;
365
123-129
-
185
Janssen H L, Zonneveld van M, Nunen A B. et al .
Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome.
Eur J Gastroenterol Hepatol.
2004;
16
801-807
-
186
Jardi van R, Rodriguez F, Buti M. et al .
Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference.
Hepatology.
2001;
34
404-410
-
187
Jilg W, Hottentrager B, Weinberger K. et al .
Prevalence of markers of hepatitis B in the adult German population.
J Med Virol.
2001;
63
96-102
-
188
Jilg W, Schmidt M, Deinhardt F.
Four-year experience with a recombinant hepatitis B vaccine.
Infection.
1989;
17
70-76
-
189
Jilg W, Schmidt M, Deinhardt F.
Inoculation failure following hepatitis B vaccination. The effect of additional vaccinations.
Dtsch Med Wochenschr.
1990;
115
1545-1548
-
190
Jonas M M, Mizerski J, Badia I B. et al .
Clinical trial of lamivudine in children with chronic hepatitis B.
N Engl J Med.
2002;
346
1706-1713
-
191
Kanaan N, Horsmans Y, Goffin E.
Lamivudine for nephrotic syndrome related to hepatitis B virus (HBV) infection.
Clin Nephrol.
2006;
65
208-210
-
192
Kanwal F, Farid M, Martin P. et al .
Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.
Am J Gastroenterol.
2006;
101
2076-2089
-
193
Kapoor D, Aggarwal S R, Singh N P. et al .
Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients.
J Viral Hepat.
1999;
6
405-409
-
194
Kapoor D, Guptan R C, Wakil S M. et al .
Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis.
J Hepatol.
2000;
33
308-312
-
195
Kelly D.
Viral hepatitis in children.
Adv Exp Med Biol.
2004;
549
83-90
-
196
Kempinska A, Kwak E J, Angel J B.
Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature.
Clin Infect Dis.
2005;
41
1277-1182
-
197
Kim K H, Ahn S H, Chung H Y. et al .
Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity.
J Gastroenterol Hepatol.
2004;
19
847-853
-
198
Knoll A, Boehm S, Hahn J. et al .
Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation.
Bone Marrow Transplant.
2004;
33
925-929
-
199
Knoll A, Hartmann A, Hamoshi H. et al .
Serological pattern „anti-HBc alone”: characterization of 552 individuals and clinical significance.
World J Gastroenterol.
2006;
12
1255-1260
-
200
Kohmoto M, Enomoto M, Tamori A. et al .
Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
J Med Virol.
2005;
75
235-239
-
201
Kondili L A, Osman H, Mutimer D.
The use of lamivudine for patients with acute hepatitis B (a series of cases).
J Viral Hepat.
2004;
11
427-431
-
202
Konopnicki D, Mocroft A, Wit de S. et al .
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.
AIDS.
2005;
19
593-601
-
203
Korenman J, Baker B, Waggoner J. et al .
Long-term remission of chronic hepatitis B after alpha-interferon therapy.
Ann Intern Med.
1991;
114
629-634
-
204
Kruger M, Boker K H, Zeidler H. et al .
Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b.
J Hepatol.
1997;
26
935-939
-
205
Kumagai K, Takagi T, Nakamura S. et al .
Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan.
Ann Oncol.
1997;
8 (Suppl 1)
107-109
-
206
Kumar M, Satapathy S, Monga R. et al .
A randomized controlled trial of lamivudine to treat acute hepatitis B.
Hepatology.
2007;
45
97-101
-
207
Kuo A, Dienstag J L, Chung R T.
Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B.
Clin Gastroenterol Hepatol.
2004;
2
266-272
-
208
Lackner H, Moser A, Benesch M. et al .
Serological and molecular response on combined antiviral treatment in children with chronic hepatitis B after pediatric malignancy.
J Clin Virol.
2002;
25 (Suppl 3)
S73-S79
-
209
Lai C L, Chien R N, Leung N W. et al .
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
N Engl J Med.
1998;
339
61-68
-
210
Lai C L, Dienstag J, Schiff E. et al .
Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.
Clin Infect Dis.
2003;
36
687-696
-
211
Lai C L, Gane E, Hsu C W. et al .
Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine vs lamivudine.
Hepatology.
2006;
44
222A
-
212
Lai C L, Gane E, Liaw Y F. et al .
Telbivudine (LdT) vs. lamivudine for chronic hepatitis B: First-year results from the international phase III globe trial.
Hepatology.
2005;
42
748A
-
213
Lai C L, Leung N, Teo E K. et al .
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.
Gastroenterology.
2005;
129
528-536
-
214
Lai C L, Shouval D, Lok A S. et al .
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
N Engl J Med.
2006;
354
1011-1020
-
215
Lampertico P, Del Ninno E, Vigano M. et al .
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.
Hepatology.
2003;
37
756-763
-
216
Lampertico P, Marzano A, Levrero M. et al .
Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B.
Hepatology.
2006;
44
693A-694A
-
217
Lampertico P, Vigano M, Manenti E. et al .
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
Hepatology.
2005;
42
1414-1419
-
218
Lang M, Neumann U, Kahl A. et al .
Long-term outcome of 27 patients after combined liver-kidney transplantation.
Transplant Proc.
2001;
33
1440-1441
-
219
Lau D T, Doo E, Park Y. et al .
Lamivudine for chronic delta hepatitis.
Hepatology.
1999;
30
546-549
-
220
Lau D T, Everhart J, Kleiner D E. et al .
Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa.
Gastroenterology.
1997;
113
1660-1667
-
221
Lau D T, Kleiner D E, Park Y. et al .
Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy.
Gastroenterology.
1999;
117
1229-1233
-
222
Lau G K, He M L, Fong D Y. et al .
Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.
Hepatology.
2002;
36
702-709
-
223
Lau G K, Liang R, Chiu E K. et al .
Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study.
Bone Marrow Transplant.
1997;
19
795-799
-
224
Lau G K, Lok A S, Liang R H. et al .
Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer.
Hepatology.
1997;
25
1497-1501
-
225
Lau G K, Piratvisuth T, Luo K X. et al .
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
N Engl J Med.
2005;
352
2682-2695
-
226
Lau G K, Suri D, Liang R. et al .
Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen.
Gastroenterology.
2002;
122
614-624
-
227
Lau G K, Yiu H H, Fong D Y. et al .
Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.
Gastroenterology.
2003;
125
1742-1749
-
228
Lau J Y, Smith H M, Chaggar K. et al .
Significance of IgM anti-hepatitis D virus (HDV) in chronic HDV infection.
J Med Virol.
1991;
33
273-276
-
229
Laubscher B, Gehri M, Roulet M. et al .
Survival of infantile fulminant hepatitis B and treatment with Lamivudine.
J Pediatr Gastroenterol Nutr.
2005;
40
518-520
-
230
Lavanchy D.
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.
J Viral Hepat.
2004;
11
97-107
-
231
Law J K, Ho J K, Hoskins P J. et al .
Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations.
Leuk Lymphoma.
2005;
46
1085-1089
-
232
Le Gal F, Gordien E, Affolabi D. et al .
Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients.
J Clin Microbiol.
2005;
43
2363-2369
-
233
Leaw S J, Yen C J, Huang W T. et al .
Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.
Ann Hematol.
2004;
83
270-275
-
234
Lee C, Gong Y, Brok J. et al .
Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis.
BMJ.
2006;
332
328-336
-
235
Lee C, Gong Y, Brok J. et al .
Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers.
Cochrane Database Syst Rev CD004790.
2006;
-
236
Lee G W, Ryu M H, Lee J L. et al .
The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin’s lymphoma who receive cytotoxic chemotherapy.
J Korean Med Sci.
2003;
18
849-854
-
237
Lee K M, Cho S W, Kim S W. et al .
Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion.
J Viral Hepat.
2002;
9
208-212
-
238
Lee W C, Wu M J, Cheng C H. et al .
Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients.
Am J Kidney Dis.
2001;
38
1074-1081
-
239
Lee Y S, Suh D J, Lim Y S. et al .
Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.
Hepatology.
2006;
43
1385-1391
-
240
Li Y H, He Y F, Jiang W Q. et al .
Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.
Cancer.
2006;
106
1320-1325
-
241
Liao S S, Li R C, Li H. et al .
Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children.
Vaccine.
1999;
17
2661-2666
-
242
Liaw Y F.
Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma.
Semin Liver Dis.
2005;
25 (Suppl 1)
40-47
-
243
Liaw Y F, Chen Y C, Sheen I S. et al .
Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection.
Gastroenterology.
2004;
126
1024-1029
-
244
Liaw Y F, Chien R N, Yeh C T.
No benefit to continue lamivudine therapy after emergence of YMDD mutations.
Antivir Ther.
2004;
9
257-262
-
245
Liaw Y F, Leung N W, Chang T T. et al .
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
Gastroenterology.
2000;
119
172-180
-
246
Liaw Y F, Sung J J, Chow W C. et al .
Lamivudine for patients with chronic hepatitis B and advanced liver disease.
N Engl J Med.
2004;
351
1521-1531
-
247
Liaw Y F, Tsai S L, Sheen I S. et al .
Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers.
Am J Gastroenterol.
1998;
93
354-359
-
248
Lim L L, Wai C T, Lee Y M. et al .
Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients.
Aliment Pharmacol Ther.
2002;
16
1939-1944
-
249
Lim S G, Krastev Z, Ng T M. et al .
Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B.
Antimicrob Agents Chemother.
2006;
50
1642-1648
-
250
Lin C C, Chen C L, Concejero A. et al .
Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients.
Am J Transplant.
2007;
7
195-200
-
251
Lin S M, Sheen I S, Chien R N. et al .
Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.
Hepatology.
1999;
29
971-975
-
252
Lin S M, Yu M L, Lee C M. et al .
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma.
J Hepatol.
2007;
46
45-52
-
253
Lo C M, Liu C L, Lau G K. et al .
Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine.
Liver Transpl.
2005;
11
807-813
-
254
Locarnini S.
Molecular virology and the development of resistant mutants: implications for therapy.
Semin Liver Dis.
2005;
25 (Suppl 1)
9-19
-
255
Locarnini S, Hatzakis A, Heathcote J. et al .
Management of antiviral resistance in patients with chronic hepatitis B.
Antivir Ther.
2004;
9
679-693
-
256
Lok A S, Lai C L.
A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children.
Hepatology.
1988;
8
1130-1133
-
257
Lok A S, Lai C L, Leung N. et al .
Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
Gastroenterology.
2003;
125
1714-1722
-
258
Lok A S, Liang R H, Chiu E K. et al .
Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.
Gastroenterology.
1991;
100
182-188
-
259
Lok A S, McMahon B J.
AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines.
Rom J Gastroenterol.
2004;
13
150-154
-
260
Looney R J, Hasan M S, Coffin D. et al .
Hepatitis B immunization of healthy elderly adults: relationship between naive CD4 + T cells and primary immune response and evaluation of GM-CSF as an adjuvant.
J Clin Immunol.
2001;
21
30-36
-
261
Lucey M R, Graham D M, Martin P. et al .
Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation.
Gut.
1992;
33
1390-1396
-
262
Madejon A, Cotonat T, Bartolome J. et al .
Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response.
Hepatology.
1994;
19
1331-1336
-
263
Manesis E K, Hadziyannis S J.
Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.
Gastroenterology.
2001;
121
101-109
-
264
Manns M P, Wedemeyer H, Cornberg M.
Treating viral hepatitis C: efficacy, side effects, and complications.
Gut.
2006;
55
1350-1359
-
265
Manzarbeitia C, Reich D J, Ortiz J A. et al .
Safe use of livers from donors with positive hepatitis B core antibody.
Liver Transpl.
2002;
8
556-561
-
266
Marangi A L, Giordano R, Montanaro A. et al .
Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination.
Am J Kidney Dis.
1994;
23
537-542
-
267
Marcellin P, Boyer N, Colin J F. et al .
Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine.
Gut.
1993;
34
S106
-
268
Marcellin P, Chang T T, Lim S G. et al .
Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B (CHB) patients.
Hepatology.
2006;
44
548A
-
269
Marcellin P, Chang T T, Lim S G. et al .
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
N Engl J Med.
2003;
348
808-816
-
270
Marcellin P, Lau G K, Bonino F. et al .
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
N Engl J Med.
2004;
351
1206-1217
-
271
Margreiter R, Kramar R, Huber C. et al .
Combined liver and kidney transplantation.
Lancet.
1984;
1
1077-1078
-
272
Maria Elzbieta S L, Marek L D.
Histological outcome of chronic hepatitis B in children treated with interferon alpha.
World J Gastroenterol.
2005;
11
7179-7182
-
273
Markovic S, Drozina G, Vovk M. et al .
Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients.
Hepatogastroenterology.
1999;
46
2925-2930
-
274
Markowitz J S, Martin P, Conrad A J. et al .
Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.
Hepatology.
1998;
28
585-589
-
275
Martinez E, Blanco J L, Arnaiz J A. et al .
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
AIDS.
2001;
15
1261-1268
-
276
Marusawa H, Chiba T.
How can we prevent viral reactivation in liver transplantation from donors with latent hepatitis B virus infection?.
J Gastroenterol.
2001;
36
212-213
-
277
Marzano A, Salizzoni M, Debernardi-Venon W. et al .
Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis.
J Hepatol.
2001;
34
903-910
-
278
Mason W S, Taylor J M.
Liver transplantation: a model for the transmission of hepatitis delta virus.
Gastroenterology.
1991;
101
1741-1743
-
279
Mast E E, Weinbaum C M, Fiore A E. et al .
A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults.
MMWR Recomm Rep.
2006;
55
1-33
-
280
Mathurin P, Mouquet C, Poynard T. et al .
Impact of hepatitis B and C virus on kidney transplantation outcome.
Hepatology.
1999;
29
257-263
-
281
Mathurin P, Thibault V, Kadidja K. et al .
Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections.
J Viral Hepat.
2000;
7
15-22
-
282
McDonald J A, Harris S, Waters J A. et al .
Effect of human immunodeficiency virus (HIV) infection on chronic hepatitis B hepatic viral antigen display.
J Hepatol.
1987;
4
337-342
-
283
McMahon B J, Alward W L, Hall D B. et al .
Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state.
J Infect Dis.
1985;
151
599-603
-
284 Mertens T, Haller O A, Klenk H D. Diagnostik und Therapie von Viruskrankheiten: Leitlinien der Gesellschaft für Virologie. München; Urban und Fischer-Verlag 2004
-
285
Mettang T, Schenk U, Thomas S. et al .
Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure. A preliminary study.
Nephron.
1996;
72
192-196
-
286
Miro J M, Laguno M, Moreno A. et al .
Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)?.
J Hepatol.
2006;
44
S140-S145
-
287
Mitsui T, Iwano K, Suzuki S. et al .
Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in historical controls.
Hepatology.
1989;
10
324-327
-
288
Mitwalli A.
Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling.
Nephron.
1996;
73
417-420
-
289
Monteyne P, Andre F E.
Is there a causal link between hepatitis B vaccination and multiple sclerosis?.
Vaccine.
2000;
18
1994-2001
-
290
Mutchnick M G, Lindsay K L, Schiff E R. et al .
Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study.
J Viral Hepat.
1999;
6
397-403
-
291
Myers R P, Tainturier M H, Ratziu V. et al .
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.
J Hepatol.
2003;
39
222-230
-
292
Nagamatsu H, Itano S, Nagaoka S. et al .
Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy.
Am J Gastroenterol.
2004;
99
2369-2375
-
293
Nagamatsu H, Kumashiro R, Itano S. et al .
Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC.
Hepatol Res.
2003;
26
293-301
-
294
Nakamura Y, Motokura T, Fujita A. et al .
Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987 - 1991.
Cancer.
1996;
78
2210-2215
-
295
Neff G W, Bonham A, Tzakis A G. et al .
Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease.
Liver Transpl.
2003;
9
239-247
-
296
Neff G W, Nery J, Lau D T. et al .
Tenofovir therapy for lamivudine resistance following liver transplantation.
Ann Pharmacother.
2004;
38
1999-2004
-
297
Neumann U P, Lang M, Moldenhauer A. et al .
Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation.
Transplantation.
2001;
71
1163-1168
-
298
Ni Y H, Huang F C, Wu T C. et al .
Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients.
Pediatr Int.
2005;
47
372-377
-
299
Niederau C, Heintges T, Lange S. et al .
Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.
N Engl J Med.
1996;
334
1422-1427
-
300
Niro G A, Ciancio A, Gaeta G B. et al .
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta.
Hepatology.
2006;
44
713-720
-
301
Ohtsu T, Sai T, Oka M. et al .
Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies.
Jpn J Clin Oncol.
1991;
21
360-365
-
302
Olausson M, Mjornstedt L, Norden G. et al .
Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients.
Am J Transplant.
2007;
7
130-136
-
303
Ollenschlager G, Kopp I, Lelgemann M. et al .
The German program for disease management guidelines. Background, methods, and development process.
Med Klin (Munich).
2006;
101
840-845
-
304
Onozawa M, Hashino S, Izumiyama K. et al .
Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection.
Transplantation.
2005;
79
616-619
-
305
Ozgenc F, Arikan C, Sertoz R Y. et al .
Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
Antivir Ther.
2004;
9
729-732
-
306
Ozguroglu M, Bilici A, Turna H. et al .
Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin’s lymphoma.
Med Oncol.
2004;
21
67-72
-
307
Palmer D R, Perry K R, Mortimer P P. et al .
Variation in the sensitivity of HBsAg screening kits.
Transfus Med.
1996;
6
311-317
-
308
Papatheodoridis G V, Dimou E, Laras A. et al .
Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.
Hepatology.
2002;
36
219-226
-
309
Papatheodoridis G V, Manesis E, Hadziyannis S J.
The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B.
J Hepatol.
2001;
34
306-313
-
310
Park J W, Park K W, Cho S H. et al .
Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study.
Am J Gastroenterol.
2005;
100
2194-2200
-
311
Pastore G, Santantonio T, Monno L. et al .
Permanent inhibition of viral replication induced by low dosage of human leukocyte interferon in patients with chronic hepatitis B.
Hepatogastroenterology.
1988;
35
57-61
-
312
Perrillo R, Hann H W, Mutimer D. et al .
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.
Gastroenterology.
2004;
126
81-90
-
313
Perrillo R P, Lai C L, Liaw Y F. et al .
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.
Hepatology.
2002;
36
186-194
-
314
Perrillo R P, Wright T, Rakela J. et al .
A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.
Hepatology.
2001;
33
424-432
-
315
Persico M, De Marino F, Russo G D. et al .
Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma.
Blood.
2002;
99
724-725
-
316
Perz J F, Armstrong G L, Farrington L A. et al .
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.
J Hepatol.
2006;
45
529-538
-
317
Peters M G, Andersen J, Lynch P. et al .
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.
Hepatology.
2006;
44
1110-1116
-
318
Peters M G, Hann H H, Martin P. et al .
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.
Gastroenterology.
2004;
126
91-101
-
319
Pineda J A, Romero-Gomez M, Diaz-Garcia F. et al .
HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis.
Hepatology.
2005;
41
779-789
-
320
Pirson Y, Alexandre G P, Ypersele C.
Long-term effect of HBs antigenemia on patient survival after renal transplantation.
N Engl J Med.
1977;
296
194-196
-
321
Poge U, Gerhardt T, Palmedo H. et al .
MDRD equations for estimation of GFR in renal transplant recipients.
Am J Transplant.
2005;
5
1306-1311
-
322
Pol S, Wesenfelder L, Dubois F. et al .
Influence of human immunodeficiency virus infection on hepatitis delta virus superinfection in chronic HBsAg carriers.
J Viral Hepat.
1994;
1
131-137
-
323
Pollicino T, Squadrito G, Cerenzia G. et al .
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection.
Gastroenterology.
2004;
126
102-110
-
324
Pontisso P, Ruvoletto M G, Fattovich G. et al .
Clinical and virological profiles in patients with multiple hepatitis virus infections.
Gastroenterology.
1993;
105
1529-1533
-
325
Poynard T, Zoulim F, Ratziu V. et al .
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.
Am J Gastroenterol.
2005;
100
1970-1980
-
326
Prakoso E, Strasser S I, Koorey D J. et al .
Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
Clin Transplant.
2006;
20
369-373
-
327
Pramoolsinsap C, Poovorawan Y, Hirsch P. et al .
Acute, hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV.
Ann Trop Med Parasitol.
1999;
93
745-751
-
328
Prieto M, Gomez M D, Berenguer M. et al .
De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.
Liver Transpl.
2001;
7
51-58
-
329
Propst T, Propst A, Lhotta K. et al .
Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination.
Am J Kidney Dis.
1998;
32
1041-1045
-
330
Protzer-Knolle U, Naumann U, Bartenschlager R. et al .
Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation.
Hepatology.
1998;
27
254-263
-
331
Puoti M, Airoldi M, Bruno R. et al .
Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects.
AIDS Rev.
2002;
4
27-35
-
332
Puoti M, Cozzi-Lepri A, Arici C. et al .
Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis.
Antivir Ther.
2006;
11
567-574
-
333
Puoti M, Torti C, Bruno R. et al .
Natural history of chronic hepatitis B in co-infected patients.
J Hepatol.
2006;
44
S65-S70
-
334
Ragni M V, Belle S H, Im K. et al .
Survival of human immunodeficiency virus-infected liver transplant recipients.
J Infect Dis.
2003;
188
1412-1420
-
335
Ragni M V, Eghtesad B, Schlesinger K W. et al .
Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease.
Liver Transpl.
2005;
11
1425-1430
-
336
Rahman F, Dahmen A, Herzog-Hauff S. et al .
Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen.
Hepatology.
2000;
31
521-527
-
337
Raimondo G, Pollicino T, Cacciola I. et al .
Occult hepatitis B virus infection.
J Hepatol.
2007;
46
160-170
-
338
Ranger-Rogez S, Denis F.
Hepatitis B mother-to-child transmission.
Expert Rev Anti Infect Ther.
2004;
2
133-145
-
339
Rehermann B, Nascimbeni M.
Immunology of hepatitis B virus and hepatitis C virus infection.
Nat Rev Immunol.
2005;
5
215-229
-
340
Rendi-Wagner P, Wiedermann G, Stemberger H. et al .
New vaccination strategies for low- and non-responders to hepatitis B vaccine.
Wien Klin Wochenschr.
2002;
114
175-180
-
341
Resti M, Azzari C, Mannelli F. et al .
Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated?.
Vaccine.
1997;
15
1338-1340
-
342
Rizzetto M.
Hepatitis D: virology, clinical and epidemiological aspects.
Acta Gastroenterol Belg.
2000;
63
221-224
-
343
Rizzetto M.
Hepatitis delta: the virus and the disease.
J Hepatol.
1990;
11 (Suppl 1)
S145-S148
-
344
Rizzetto M, Macagno S, Chiaberge E. et al .
Liver transplantation in hepatitis delta virus disease.
Lancet.
1987;
2
469-471
-
345
Rizzetto M, Verme G, Recchia S. et al .
Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment.
Ann Intern Med.
1983;
98
437-441
-
346
Robert Koch-Institut .
Zur Situation wichtiger Infektionskrankheiten in Deutschland: Virushepatitis B, C und D im Jahr 2005.
Epidem Bull.
2006;
46
-
347
Robert Koch-Institut .
Mitteilungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Hinweise für Ärzte zum Aufklärungsbedarf bei Schutzimpfungen.
Epidem Bull.
2004;
6
33-52
-
348
Robert Koch-Institut .
Virushepatitis B, C und D im Jahre 2004.
Epidem Bull.
2005;
46
421-236
-
349
Robert Koch-Institut .
Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand Juli 2006.
Epidem Bull.
2006;
30
235-254
-
350
Roche B, Samuel D, Gigou M. et al .
De novo and apparent de novo hepatitis B virus infection after liver transplantation.
J Hepatol.
1997;
26
517-526
-
351
Rockstroh J K.
Influence of viral hepatitis on HIV infection.
J Hepatol.
2006;
44
S25-S27
-
352
Rodella A, Galli C, Terlenghi L. et al .
Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B.
J Clin Virol.
2006;
37
206-212
-
353
Romand F, Michallet M, Pichoud C. et al .
Hepatitis B virus reactivation after allogeneic bone marrow transplantation in a patient previously cured of hepatitis B.
Gastroenterol Clin Biol.
1999;
23
770-774
-
354
Roque-Afonso A M, Feray C, Samuel D. et al .
Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors.
Gut.
2002;
50
95-99
-
355
Rosenau J, Bahr M J, Tillmann H L. et al .
Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection.
J Hepatol.
2001;
34
895-902
-
356
Rosenau J, Hooman N, Rifai K. et al .
Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response.
Transpl Int.
2006;
19
828-833
-
357
Rosina F, Pintus C, Meschievitz C. et al .
A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study.
Hepatology.
1991;
13
1052-1056
-
358
Rosina F, Rizzetto M.
Treatment of chronic type D (delta) hepatitis with alpha interferon.
Semin Liver Dis.
1989;
9
264-266
-
359
Rosman A S, Basu P, Galvin K. et al .
Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial.
Am J Med.
1997;
103
217-222
-
360
Rossi G, Pelizzari A, Motta M. et al .
Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAG carriers with lymphoid malignancies treated with chemotherapy.
Br J Haematol.
2001;
115
58-62
-
361
Ruiz R, Kunitake H, Wilkinson A H. et al .
Long-term analysis of combined liver and kidney transplantation at a single center.
Arch Surg.
2006;
141
735-741
-
362
Ryu S H, Chung Y H, Choi M H. et al .
Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study.
J Hepatol.
2003;
39
614-619
-
363
Sadovnick A D, Scheifele D W.
School-based hepatitis B vaccination programme and adolescent multiple sclerosis.
Lancet.
2000;
355
549-550
-
364
Sagnelli E, Coppola N, Scolastico C. et al .
Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis.
Hepatology.
2000;
32
1106-1110
-
365
Sagnelli E, Pasquale G, Coppola N. et al .
Influence of chronic coinfection with hepatitis B and C virus on liver histology.
Infection.
2004;
32
144-148
-
366
Sakallioglu O, Gok F, Kalman S. et al .
Hepatitis B complicated focal segmental glomerulosclerosis.
J Nephrol.
2005;
18
433-435
-
367
Saltik-Temizel I N, Kocak N, Demir H.
Interferon-alpha and lamivudine combination therapy of children with chronic hepatitis b infection who were interferon-alpha nonresponders.
Pediatr Infect Dis J.
2004;
23
466-468
-
368
Saltik-Temizel I N, Kocak N, Demir H.
Lamivudine and high-dose interferon-alpha combination therapy for naive children with chronic hepatitis B infection.
J Clin Gastroenterol.
2005;
39
68-70
-
369
Samuel D, Muller R, Alexander G. et al .
Liver transplantation in European patients with the hepatitis B surface antigen.
N Engl J Med.
1993;
329
1842-1847
-
370
Samuel D, Zignego A L, Reynes M. et al .
Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis.
Hepatology.
1995;
21
333-339
-
371
Sanchez-Fueyo A, Rimola A, Grande L. et al .
Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.
Hepatology.
2000;
31
496-501
-
372
Saracco G, Rosina F, Brunetto M R. et al .
Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection.
J Hepatol.
1987;
5
274-281
-
373
Sarrecchia C, Cappelli A, Aiello P.
HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb.
J Infect Chemother.
2005;
11
189-191
-
374
Schattner A.
Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines.
Vaccine.
2005;
23
3876-3886
-
375
Scheiblauer H, Soboll H, Nick S.
Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection.
J Med Virol.
2006;
78 (Suppl 1)
S66-S70
-
376
Schiff E R, Lai C L, Hadziyannis S. et al .
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.
Hepatology.
2003;
38
1419-1427
-
377
Schildgen O, Sirma H, Funk A. et al .
Variant of hepatitis B virus with primary resistance to adefovir.
N Engl J Med.
2006;
354
1807-1812
-
378
Schirmacher P, Fleig W E, Tannapfel A. et al .
Bioptic diagnosis of chronic hepatitis. Results of an evidence-based consensus conference of the German Society of Pathology, of the German Society for Digestive and Metabolic Diseases and of Compensated Hepatitis (HepNet).
Pathologe.
2004;
25
337-348
-
379
Schmilovitz-Weiss H, Ben Ari Z, Sikuler E. et al .
Lamivudine treatment for acute severe hepatitis B: a pilot study.
Liver Int.
2004;
24
547-551
-
380
Schmutz G, Nelson M, Lutz T. et al .
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
AIDS.
2006;
20
1951-1954
-
381
Seaworth B, Drucker J, Starling J. et al .
Hepatitis B vaccines in patients with chronic renal failure before dialysis.
J Infect Dis.
1988;
157
332-337
-
382
Segovia R, Sanchez-Fueyo A, Rimola A. et al .
Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation.
Liver Transpl.
2001;
7
106-112
-
383
Seth P, Alrajhi A A, Kagevi I. et al .
Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease.
Bone Marrow Transplant.
2002;
30
189-194
-
384
Shattock A G, Morris M C.
Evaluation of commercial enzyme immunoassays for detection of hepatitis delta antigen and anti-hepatitis delta virus (HDV) and immunoglobulin M anti-HDV antibodies.
J Clin Microbiol.
1991;
29
1873-1876
-
385
Sheldon J, Camino N, Rodes B. et al .
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
Antivir Ther.
2005;
10
727-734
-
386
Sheldon J A, Corral A, Rodes B. et al .
Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir.
AIDS.
2005;
19
2036-2038
-
387
Sheng W H, Hung C C, Kao J H. et al .
Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.
Clin Infect Dis.
2007;
44
988-995
-
388
Sherman M, Peltekian K M, Lee C.
Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population.
Hepatology.
1995;
22
432-438
-
389
Sherman M, Yurdaydin C, Sollano J. et al .
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
Gastroenterology.
2006;
130
2039-2049
-
390
Shibolet O, Ilan Y, Gillis S. et al .
Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers.
Blood.
2002;
100
391-396
-
391
Silvestri F, Sperotto A, Ermacora A. et al .
Lamivudine for the prevention of hepatitis B virus reactivation during autologous stem cell transplantation. A case report.
Haematologica.
2000;
85
327-329
-
392
Smedile A, Farci P, Verme G. et al .
Influence of delta infection on severity of hepatitis B.
Lancet.
1982;
2
945-947
-
393
Sokal E.
Drug treatment of pediatric chronic hepatitis B.
Paediatr Drugs.
2002;
4
361-369
-
394
Sokal E M, Kelly D A, Mizerski J. et al .
Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B.
Hepatology.
2006;
43
225-232
-
395
Soriano V, Barreiro P, Nunez M.
Management of chronic hepatitis B and C in HIV-coinfected patients.
J Antimicrob Chemother.
2006;
57
815-818
-
396
Soriano V, Puoti M, Bonacini M. et al .
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
AIDS.
2005;
19
221-240
-
397
Spengler U, Lichterfeld M, Rockstroh J K.
Antiretroviral drug toxicity - a challenge for the hepatologist?.
J Hepatol.
2002;
36
283-294
-
398
Sponseller C A, Bacon B R, Di Bisceglie A M.
Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.
Liver Transpl.
2000;
6
715-720
-
399
Starkel P, Stoffel M, Lerut J. et al .
Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients.
Liver Transpl.
2005;
11
1228-1234
-
400
Steinmuller T, Seehofer D, Rayes N. et al .
Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease.
Hepatology.
2002;
35
1528-1535
-
401
Stevens C E, Alter H J, Taylor P E. et al .
Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy.
N Engl J Med.
1984;
311
496-501
-
402
Su C W, Huang Y H, Huo T I. et al .
Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients.
Gastroenterology.
2006;
130
1625-1635
-
403
Su G G, Pan K H, Zhao N F. et al .
Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy.
World J Gastroenterol.
2004;
10
910-912
-
404
Sung J JY, Lai J Y, Zeuzem S. et al .
A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): Week 52 analysis.
Journal of Hepatology.
2003;
38
25-26
-
405
Tabor E.
Infections by hepatitis B surface antigen gene mutants in Europe and North America.
J Med Virol.
2006;
78 (Suppl 1)
S43-S47
-
406
Tang J R, Cova L, Lamelin J P. et al .
Clinical relevance of the detection of hepatitis delta virus RNA in serum by RNA hybridization and polymerase chain reaction.
J Hepatol.
1994;
21
953-960
-
407
Tassopoulos N C, Papaevangelou G J, Sjogren M H. et al .
Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults.
Gastroenterology.
1987;
92
1844-1850
-
408
Tenderich G, Zittermann A, Prohaska W. et al .
Frequent detection of hepatitis B core antibodies in heart transplant recipients without preceding hepatitis B infection.
Transplant Proc.
2005;
37
4522-4524
-
409
Tenney D, Baldick C J, Rose R E. et al .
Only a subset of HBV substitutions at entecavir resistance residues lead to phenotypic resistance and virologic rebound.
Hepatology.
2006;
44
253A-254A
-
410
ter Borg F, Smorenburg S, Man R A. et al .
Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy.
Dig Dis Sci.
1998;
43
2267-2270
-
411
Terrault de N, Roche B, Samuel D.
Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective.
Liver Transpl.
2005;
11
716-732
-
412
Thierfelder W, Hellenbrand W, Meisel H. et al .
Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998.
Eur J Epidemiol.
2001;
17
429-435
-
413
Thio C L.
Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment.
Semin Liver Dis.
2003;
23
125-136
-
414
Thio C L, Seaberg E C, Skolasky R Jr. et al .
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).
Lancet.
2002;
360
1921-1926
-
415 Thomas H C, Lemon S, Zuckerman A J. Viral Hepatitis. Thomas HC, Lemon S, Zuckerman AJ Blackwell Publishing 2005
-
416
Tillmann H L, Hadem J, Leifeld L. et al .
Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience.
J Viral Hepat.
2006;
13
256-263
-
417
Tseng P L, Lu S N, Tung H D. et al .
Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis.
J Viral Hepat.
2005;
12
386-392
-
418
Tsutsumi Y, Tanaka J, Kawamura T. et al .
Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin’s lymphoma.
Ann Hematol.
2004;
83
58-60
-
419
Uemoto S, Inomata Y, Sannomiya A. et al .
Posttransplant hepatitis B infection in liver transplantation with hepatitis B core antibody-positive donors.
Transplant Proc.
1998;
30
134-135
-
420
Bommel van F, Wunsche T, Mauss S. et al .
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.
Hepatology.
2004;
40
1421-1425
-
421
Bommel van F, Zollner B, Sarrazin C. et al .
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
Hepatology.
2006;
44
318-325
-
422
Van Damme P, Kane M, Meheus A.
Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board.
BMJ.
1997;
314
1033-1036
-
423
Nunen A B, Hansen B E, Suh D J. et al .
Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.
Gut.
2003;
52
420-424
-
424
Zonneveld van M, Nunen van A B, Niesters H G. et al .
Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection.
J Viral Hepat.
2003;
10
294-297
-
425
Vassiliadis van T, Garipidou V, Tziomalos K. et al .
Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy - a prospective case series.
Am J Hematol.
2005;
80
197-203
-
426
Verme G, Brunetto M R, Oliveri F. et al .
Role of hepatitis delta virus infection in hepatocellular carcinoma.
Dig Dis Sci.
1991;
36
1134-1136
-
427
Villa E, Grottola A, Buttafoco P. et al .
High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial.
Am J Gastroenterol.
2001;
96
2973-2977
-
428
Villeneuve E, Vincelette J, Villeneuve J P.
Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation.
Can J Gastroenterol.
2000;
14 (Suppl B)
59B-62B
-
429
Villeneuve J P, Condreay L D, Willems B. et al .
Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.
Hepatology.
2000;
31
207-210
-
430
Villeneuve J P, Durantel D, Durantel S. et al .
Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.
J Hepatol.
2003;
39
1085-1089
-
431
Vo Thi D H, Bourgois A, Bontems P. et al .
Chronic hepatitis B infection: long term comparison of children receiving interferon alpha and untreated controls.
J Pediatr Gastroenterol Nutr.
2005;
40
141-145
-
432
Wai C T, Chu C J, Hussain M. et al .
HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C.
Hepatology.
2002;
36
1425-1430
-
433
Wainwright R B, Bulkow L R, Parkinson A J. et al .
Protection provided by hepatitis B vaccine in a Yupik Eskimo population - results of a 10-year study.
J Infect Dis.
1997;
175
674-677
-
434
Waked I, Amin M, Abd E F. et al .
Experience with interferon in chronic hepatitis B in Egypt.
J Chemother.
1990;
2
310-318
-
435
Walker U A, Bauerle J, Laguno M. et al .
Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine.
Hepatology.
2004;
39
311-317
-
436
Walter J, Radun D, Claus H. et al .
Hepatitis B and C risk factors in Germany - results of the national surveillance.
Gesundheitswesen.
2005;
67
441-447
-
437
Wands J R, Chura C M, Roll F J. et al .
Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders.
Gastroenterology.
1975;
68
105-112
-
438
Wartelle-Bladou C, Lafon J, Trepo C. et al .
Successful combination therapy of polyarteritis nodosa associated with a pre-core promoter mutant hepatitis B virus infection.
J Hepatol.
2001;
34
774-779
-
439
Watson B, West D J, Chilkatowsky A. et al .
Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine.
Vaccine.
2001;
19
3164-3168
-
440
Weber B.
Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact.
J Clin Virol.
2005;
32
102-112
-
441
Wedemeyer H, Cornberg M, Tegtmeyer B. et al .
Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication.
Clin Microbiol Infect.
2004;
10
70-72
-
442
Weltman M D, Brotodihardjo A, Crewe E B. et al .
Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment.
J Viral Hepat.
1995;
2
39-45
-
443
Wen Y K, Chen M L.
Remission of hepatitis B virus-associated membranoproliferative glomerulonephritis in a cirrhotic patient after lamivudine therapy.
Clin Nephrol.
2006;
65
211-215
-
444
West D J, Calandra G B.
Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination.
Vaccine.
1996;
14
1019-1027
-
445
Westhoff T H, Jochimsen F, Schmittel A. et al .
Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.
Blood.
2003;
102
1930
-
446
Westland C, Delaney W, Yang H. et al .
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.
Gastroenterology.
2003;
125
107-116
-
447
Westland C E, Yang H, Delaney W E. et al .
Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.
Hepatology.
2003;
38
96-103
-
448
Whittle H, Jaffar S, Wansbrough M. et al .
Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children.
BMJ.
2002;
325
569
-
449
Wiegand J, Hasenclever D, Tillman H L.
Should treatment of hepatitis B depend on HBV genotypes? - A hypothesis generated from an explorative analysis of published evidence.
Hepatology.
2006;
44
564A-565A
-
450
Williams R.
Global challenges in liver disease.
Hepatology.
2006;
44
521-526
-
451
Wintermeyer P, Gerner P, Gehring S. et al .
Prevalence of hepatitis B virus precore stop codon mutations in chronically infected children.
World J Gastroenterol.
2006;
12
2235-2238
-
452
Wismans P, Hattum van J, Stelling T. et al .
Effect of supplementary vaccination in healthy non-responders to hepatitis B vaccination.
Hepatogastroenterology.
1988;
35
78-79
-
453
Wit F W, Weverling G J, Weel J. et al .
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
J Infect Dis.
2002;
186
23-31
-
454
Wolters L M, Nunen A B, Honkoop van P. et al .
Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus.
J Viral Hepat.
2000;
7
428-434
-
455
Wong D K, Cheung A M, O’Rourke K. et al .
Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.
Ann Intern Med.
1993;
119
312-323
-
456
Wong D K, Yim C, Naylor C D. et al .
Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population.
Gastroenterology.
1995;
108
165-171
-
457
Wong V W, Chan H L, Wong M L. et al .
Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants.
Aliment Pharmacol Ther.
2004;
19
323-329
-
458
World Health Organisation .
Hepatitis Delta. Electronic Citation.
2001;
, http://www.who.int/csr/
-
459
World Health Organisation.
Hepatitis B. Electronic Citation.
2002;
, http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf
-
460
Wursthorn K, Buggisch P, Lutgehetmann M. et al .
Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV.
Antivir Ther.
2006;
11
647-652
-
461
Wursthorn K, Lutgehetmann M, Dandri M. et al .
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
Hepatology.
2006;
44
675-684
-
462
Yang B, Zhang B, Xu Y. et al .
Prospective study of early detection for primary liver cancer.
J Cancer Res Clin Oncol.
1997;
123
357-360
-
463
Yang H I, Lu S N, Liaw Y F. et al .
Hepatitis B e antigen and the risk of hepatocellular carcinoma.
N Engl J Med.
2002;
347
168-174
-
464
Yao F Y, Terrault N A, Freise C. et al .
Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.
Hepatology.
2001;
34
411-416
-
465
Yeo W, Chan P K, Ho W M. et al .
Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
J Clin Oncol.
2004;
22
927-934
-
466
Yeo W, Chan P K, Zhong S. et al .
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.
J Med Virol.
2000;
62
299-307
-
467
Yeo W, Johnson P J.
Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.
Hepatology.
2006;
43
209-220
-
468
Yeo W, Steinberg J L, Tam J S. et al .
Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy.
J Med Virol.
1999;
59
263-269
-
469
Yeo W, Zee B, Zhong S. et al .
Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.
Br J Cancer.
2004;
90
1306-1311
-
470
Yu A S, Vierling J M, Colquhoun S D. et al .
Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy.
Liver Transpl.
2001;
7
513-517
-
471
Yuen M F, Sablon E, Hui C K. et al .
Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
Hepatology.
2001;
34
785-791
-
472
Yurdaydin C, Bozkaya H, Gurel S. et al .
Famciclovir treatment of chronic delta hepatitis.
J Hepatol.
2002;
37
266-271
-
473
Yurdaydin C, Wedemeyer H, Zachou K. et al .
A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus adefovir dipivoxil vs. pegylated interferon-alfa-2a plus placebo vs. adefovir dipivoxil for the treatment of chronic delta hepatitis.
Hepatology.
2006;
44
230A
-
474
Zanetti A R, Mariano A, Romano L. et al .
Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.
Lancet.
2005;
366
1379-1384
-
475
Zarski J P, Bohn B, Bastie A. et al .
Characteristics of patients with dual infection by hepatitis B and C viruses.
J Hepatol.
1998;
28
27-33
-
476
Zavaglia C, Severini R, Tinelli C. et al .
A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B.
Dig Dis Sci.
2000;
45
690-696
-
477
Zignego A L, Fontana R, Puliti S. et al .
Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection.
Arch Virol.
1997;
142
535-544
-
478
Zollner B, Schafer P, Feucht H H. et al .
Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy.
J Med Virol.
2001;
65
659-663
-
479
Zoulim F.
New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA.
J Hepatol.
2005;
42
302-308
-
480
Zuccotti G V, Cucchi C, Gracchi V. et al .
A 1-year trial of lamivudine for chronic hepatitis B in children.
J Int Med Res.
2002;
30
200-202
-
481
Zylberberg H, Jiang J, Pialoux G. et al .
Alpha-interferon for chronic active hepatitis B in human immunodeficiency virus-infected patients.
Gastroenterol Clin Biol.
1996;
20
968-971
Prof. Dr. Michael P. Manns
Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
Carl-Neuberg-Straße 1
30625 Hannover
eMail: manns.michael@mh-hannover.de
